Switch to Budesonide/Formoterol Easyhaler Inhalation from other inhalers in asthma patients; A real-life study Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Addition of formoterol Turbuhaler® to budesonide Turbuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial Source: Eur Respir J 2001; 18: Suppl. 33, 330s Year: 2001
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Safety of formoterol turbuhaler when used as a reliever therapy in asthma (the RELIEF study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Patient inhaler satisfaction with Spiromax Budesonide/Formoterol versus Diskus Fluticasone/Salmeterol in COPD Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007